Harmony Biosciences Holdings Inc. (HRMY)
NASDAQ: HRMYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
HRMY stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.91B
- P/E (TTM)
- 10.79
- Forward P/E
- 5.37
- EPS (TTM)
- $3.02
- Dividend yield
- None
- 52-week range
- 25.90 – 43.49
- Day range
- 32.51 – 33.43
- Volume / Avg
- 582.64K / 1.01M
- Beta
- —
- Shares outstanding
- 58.72M
52-week range
HRMY stock today
Harmony Biosciences (HRMY) closed at $32.59 on Nov 20, down 1.18% (-$0.39), versus the S&P 500's 3.70% decline. At this level, HRMY sits in the middle of its 52-week range of $25.90 to $43.49: 25.1% below the high, set on Sep 3, 2026 and 25.8% above the low. HRMY is down 12.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 5.0%.
Harmony Biosciences trades at 10.8x its trailing twelve-month earnings per share of $3.02. Its forward P/E of 5.4x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Harmony Biosciences
Company profileHarmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD).
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Jeffrey M. Dayno M.D.
- Headquarters
- Plymouth Meeting, PA
- Employees
- 293
- IPO year
- 2020
- Website
- harmonybiosciences.com
Financial highlights
Full financialsIn fiscal 2025, Harmony Biosciences generated $868.5 million in revenue, up 21.5% from fiscal 2024, its 6th consecutive year of revenue growth. Net income was $158.7 million (+9.1% year over year), for a net margin of 18.3% versus a median of 20.4% in the prior 5 years. Gross margin was 77.2% (down from 78.1%) and operating margin 24.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $868.45M | $714.73M | $582.02M | $437.86M | $305.44M |
| Growth | +21.51% | +22.80% | +32.93% | +43.35% | +91.21% |
| Net income | $158.69M | $145.49M | $128.85M | $181.47M | $34.60M |
| EPS (diluted) | $2.71 | $2.51 | $2.13 | $2.97 | $0.58 |
Analyst forecast
ForecastConsensus (12 analysts)
buy
Avg. price target
$48.08+47.53%
- Strong buy 2
- Buy 6
- Hold 3
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $0.87 vs $1.00
- Surprise
- -13.00%
HRMY news
All HRMY news- Harmony Biosciences to Participate in Upcoming Investor ConferencesGlobeNewswire
- HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix GrowthNasdaqHRMY, TGTX, TAK, TARS
- Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class ProfileGlobeNewswire
- GSK Q3 Earnings Top Mark, Stock Down on Soft Vaccines SalesNasdaqGSK, JNJ, TGTX, HRMY
- Harmony Biosciences Grapples With A Leadership Transition That Spooked InvestorsInvestor's Business Daily
- BHC Q3 Earnings Preview: Here's What You Should KnowNasdaqBHC, GILD, VRTX, HRMY
- TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study DataNasdaqTNGX, HALO, TGTX, HRMY
- RDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales FallNasdaqRDY, HALO, TGTX, HRMY
Harmony Biosciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AUPHAurinia Pharmaceuticals Inc | 14.70 | -1.28% | $1.97B | vs HRMY |
| TRVITrevi Therapeutics Inc. | 13.35 | -2.70% | $1.90B | vs HRMY |
| BHVNBiohaven Ltd. | 12.39 | -9.23% | $1.87B | vs HRMY |
| IMNMImmunome Inc. | 15.69 | -5.54% | $1.85B | vs HRMY |
| VERAVera Therapeutics Inc. Class A | 25.45 | -4.86% | $1.84B | vs HRMY |
| SEPNSepterna Inc. | 38.61 | -1.51% | $1.84B | vs HRMY |
| MRVIMaravai LifeSciences Holdings Inc. Class A | 6.98 | -2.92% | $1.81B | vs HRMY |
| ZYMEZymeworks Inc. | 26.14 | -2.68% | $1.81B | vs HRMY |
Indexes, lists and sector
Harmony Biosciences stock FAQ
What is Harmony Biosciences's stock price today?
HRMY last traded at $32.59 as of Nov 20, 4:00 PM EST, down 1.18% on the day. Prices are delayed at least 15 minutes.
What is HRMY's P/E ratio?
HRMY trades at a trailing P/E ratio of 10.79 and a forward P/E of 5.37.
Who is Harmony Biosciences's CEO?
Dr. Jeffrey M. Dayno M.D. is the chief executive officer of Harmony Biosciences Holdings Inc., which has about 293 employees.
What is the HRMY 52-week high?
The 52-week high for HRMY is $43.49 and the 52-week low is $25.90. The stock is currently 25.1% below its high.